Robert P Edwards

List of Publications by Year
in descending order

81 papers	3,906 citations	236925 25 h-index	128289 60 g-index
81 all docs	81 docs citations	81 times ranked	8833 citing authors

#	Article	IF	Citations
1	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
2	Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood, 2011, 118, 5498-5505.	1.4	431
3	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
4	Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
5	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
6	Diagnosis and Treatment of Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 943-964.	2.2	185
7	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
8	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
9	PGE₂-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells. Immunological Investigations, 2012, 41, 635-657.	2.0	131
10	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
11	Adipose-Derived Stems Cells and Their Role in Human Cancer Development, Growth, Progression, and Metastasis: A Systematic Review. Cancer Research, 2015, 75, 1161-1168.	0.9	100
12	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. International Journal of Cancer, 1996, 68, 276-284.	5.1	81
13	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
14	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
15	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS). Clinical Infectious Diseases, 2022, 75, e630-e644.	5.8	65
16	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
17	A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunology, Immunotherapy, 2010, 59, 293-301.	4.2	57
18	Prognosis and Conditional Disease-Free Survival Among Patients With Ovarian Cancer. Journal of Clinical Oncology, 2014, 32, 4102-4112.	1.6	57

#	Article	IF	Citations
19	Synergistic COX2 Induction by IFNÎ³ and TNFÎ± Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunology Research, 2016, 4, 303-311.	3.4	53
20	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	6.4	39
21	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
22	Changes in inflammatory endometrial cancer risk biomarkers in individuals undergoing surgical weight loss. Gynecologic Oncology, 2017, 147, 133-138.	1.4	33
23	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1114-1124.	2.5	32
24	Helicase-Driven Activation of NFÎºB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment. Cancer Research, 2018, 78, 4292-4302.	0.9	30
25	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
26	What is driving the decreased incidence of preterm birth during the coronavirus disease 2019 pandemic?. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100330.	2.6	27
27	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	5.1	25
28	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
29	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
30	Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers, 2020, 12, 3733.	3.7	24
31	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
32	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
33	Breastfeeding factors and risk of epithelial ovarian cancer. Gynecologic Oncology, 2019, 153, 116-122.	1.4	22
34	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	1.9	20
35	Patient and provider factors associated with endometrial Pipelle sampling failure. Gynecologic Oncology, 2017, 144, 324-328.	1.4	20
36	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19

#	Article	IF	Citations
37	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
38	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	2.9	17
39	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	6.4	16
40	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2019, 30, 537-547.	1.8	16
41	Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. Clinical Cancer Research, 2022, 28, 2038-2049.	7.0	16
42	Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Science Translational Medicine, 2021, 13, eabf8495.	12.4	16
43	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
44	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
45	Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage. Gynecologic Oncology, 2018, 150, 112-118.	1.4	15
46	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	6.4	13
47	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
48	MUC1 Positive, Kras and Pten Driven Mouse Gynecologic Tumors Replicate Human Tumors and Vary in Survival and Nuclear Grade Based on Anatomical Location. PLoS ONE, 2014, 9, e102409.	2.5	12
49	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
50	Improved bowel function after gynecological surgery with epidural bupivacaine-fentanyl than bupivacaine-morphine infusion. Canadian Journal of Anaesthesia, 2000, 47, 406-411.	1.6	11
51	An exploratory investigation of links between changes in adipokines and quality of life in individuals undergoing weight loss interventions: Possible implications for cancer research. Gynecologic Oncology, 2014, 133, 67-72.	1.4	11
52	Assessment of Multifactor Geneâ€"Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	2.5	10
53	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	2.5	10
54	Same-day discharge after minimal invasive hysterectomy: Applications for improved value of care. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 259, 140-145.	1.1	10

#	Article	IF	Citations
55	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	2.5	9
56	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. International Journal of Gynecological Cancer, 2017, 27, 11-16.	2.5	9
57	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
58	Metabolic Syndrome in Endometrial Cancer Patients: Systematic Review. Metabolic Syndrome and Related Disorders, 2019, 17, 241-249.	1.3	9
59	Magnetic resonance imaging response in patients treated with definitive radiation therapy for medically inoperable endometrial cancerâ€"Does it predict treatment response?. Brachytherapy, 2019, 18, 437-444.	0.5	8
60	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	2.8	8
61	Not a Humbug: the evolution of patient-centred medical decision-making. Evidence-Based Medicine, 2015, 20, 193-197.	0.6	7
62	A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget, 2016, 7, 7381-7389.	1.8	7
63	Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 626-631.	2.5	6
64	Endometrial cancer associated biomarkers in bariatric surgery candidates: exploration of racial differences. Surgery for Obesity and Related Diseases, 2017, 13, 862-868.	1.2	6
65	Relationships Between a History of Abuse, Changes in Body Mass Index, Physical Health, and Self-Reported Depression in Female Bariatric Surgery Patients. Bariatric Surgical Patient Care, 2019, 14, 113-119.	0.5	5
66	Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registry data. Cancer Medicine, 2020, 9, 7388-7397.	2.8	5
67	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
68	Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 2017, 146, 137-145.	1.4	4
69	Circulating CD14 + HLAâ€ÐR lo/â˜' monocytic cells as a biomarker for epithelial ovarian cancer progression. American Journal of Reproductive Immunology, 2021, 85, e13343.	1.2	4
70	Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?. Gynecologic Oncology, 2022, 165, 60-66.	1.4	4
71	In vitro chemoresponse in metachronous pairs of ovarian cancers. Anticancer Research, 2014, 34, 7191-6.	1.1	4
72	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3

#	Article	IF	Citations
73	Do air gaps with image-guided vaginal cuff brachytherapy impact failureÂrates in patients with high-intermediate risk FIGO Stage I endometrial cancer?. Brachytherapy, 2021, 20, 512-518.	0.5	3
74	Endometrial cancer risk factors in singapore chinese: A prospective cohort study. Annals of Epidemiology, 2022, , .	1.9	3
75	Stakeholder involvement is essential for patient centered applications of Google Trends research. Surgery for Obesity and Related Diseases, 2014, 10, 370-371.	1.2	2
76	Gestational weight gain and risk of epithelial ovarian cancer. Cancer Causes and Control, 2021, 32, 537-545.	1.8	1
77	Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. International Journal of Cancer, 1996, 68, 276-284.	5.1	1
78	Regional Therapies for Advanced Cancer: Update for 2016. Annals of Surgical Oncology, 2016, 23, 1452-1453.	1.5	0
79	Together We Make a Difference. Annals of Surgical Oncology, 2018, 25, 1794-1796.	1.5	0
80	It Is Time. Annals of Surgical Oncology, 2019, 26, 1963-1966.	1.5	0
81	Involvement of regulatory T cells and Th17 cells in ovarian endometriosis and ovarian epithelial tumors. FASEB Journal, 2008, 22, 1078.22.	0.5	0